Balloon angioplasty is increasingly being used to carry out various specific tasks during surgeries, such as scoring, cutting, and drug eluting. Manufacturers of angioplasty balloons are focusing on improving patient outcomes by constantly upgrading their existing products.
Balloon angioplasty is widely preferred for being minimally invasive, and can be performed under local anaesthesia, wherein, the patient can be discharged within 24 hours after the surgery, in most cases. Moreover, drug-coated balloon angioplasty, in particular, results in significantly lower post-surgery care, and has been associated with lesser long-term reintervention rates as compared to regular angioplasty. On the back of these factors, Fact.MR estimates the global angioplasty balloons market to be valued at US$ 2.4 Bn in 2020.
For detailed insights on enhancing your product footprint, request a sample here-
Analysts at Fact.MR opine that, Asia Pacific is emerging as a rapidly-growing regional market, due to the development of healthcare infrastructure and increase in medical expenditure in the region. This would be particularly significant during the forecast period, as the incidence of CVD is set to grow, alongside increased healthcare spending in APAC. These factors are opening up a plethora of opportunities for manufacturers in the APAC angioplasty balloons market.